Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 2014-03, Vol.53 (3), p.420-423 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 423 |
|---|---|
| container_issue | 3 |
| container_start_page | 420 |
| container_title | Acta oncologica |
| container_volume | 53 |
| creator | Poullenot, Florian Bioulac-Sage, Paulette Laumonier, Hervé Saric, Jean Carteret, Thibault Blanc, Jean-Frédéric |
| description | |
| doi_str_mv | 10.3109/0284186X.2013.795286 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_0284186X_2013_795286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_0284186X_2013_795286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-b0a53e66c35710b8219bcc377ddbdb1bc97d73e23556be1b8f3b0f166a501f6d3</originalsourceid><addsrcrecordid>eNp9kN1q1UAUhQdR7Gn1DUT2C-Q4P51J4oVSDtUWCoJW6F2Yn52eKZNMmJlQ-jI-qwlpvfRq3ay1114fIR8Y3QtG20-UN-esUXd7TpnY163kjXpFdkxJVnGu7l6T3WqpVs8JOc35gVLKRS3fkpNFmGhkvSN_rnDSJVoMYQ46gdXJ-jEOGkpCXdCBeYIck-5x9AYefTmCjcMUsCAk7XwM8d5bHSBhnuKYEbS1MTk_3kOJMPy8PFz_ugWbfMHk9Wc4xDk4eETIJU5Qjrg1DTiWr3Bh4lygj_P6Scb8jrzpdcj4_lnPyO9vl7eHq-rmx_frw8VNZQVvS2WolgKVskLWjJqGs9ZYK-raOeMMM7atXS2QCymVQWaaXhjaM6W0pKxXTpyR8-2uTTHnhH03JT_o9NQx2q24uxfc3Yq723AvsY9bbJrNgO5f6IXvYviyGfzYxzToI-pQjgtk7B6WkeOy6f8NfwEeVJLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Taylor & Francis Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Poullenot, Florian ; Bioulac-Sage, Paulette ; Laumonier, Hervé ; Saric, Jean ; Carteret, Thibault ; Blanc, Jean-Frédéric</creator><creatorcontrib>Poullenot, Florian ; Bioulac-Sage, Paulette ; Laumonier, Hervé ; Saric, Jean ; Carteret, Thibault ; Blanc, Jean-Frédéric</creatorcontrib><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/0284186X.2013.795286</identifier><identifier>PMID: 23713857</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma, Hepatocellular - diagnostic imaging ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - surgery ; Dose-Response Relationship, Drug ; Humans ; Liver Neoplasms - diagnostic imaging ; Liver Neoplasms - drug therapy ; Liver Neoplasms - surgery ; Male ; Middle Aged ; Niacinamide - adverse effects ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - adverse effects ; Phenylurea Compounds - therapeutic use ; Radiography ; Treatment Outcome</subject><ispartof>Acta oncologica, 2014-03, Vol.53 (3), p.420-423</ispartof><rights>2014 Informa Healthcare 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-b0a53e66c35710b8219bcc377ddbdb1bc97d73e23556be1b8f3b0f166a501f6d3</citedby><cites>FETCH-LOGICAL-c329t-b0a53e66c35710b8219bcc377ddbdb1bc97d73e23556be1b8f3b0f166a501f6d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/0284186X.2013.795286$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/0284186X.2013.795286$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,61194,61375</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23713857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poullenot, Florian</creatorcontrib><creatorcontrib>Bioulac-Sage, Paulette</creatorcontrib><creatorcontrib>Laumonier, Hervé</creatorcontrib><creatorcontrib>Saric, Jean</creatorcontrib><creatorcontrib>Carteret, Thibault</creatorcontrib><creatorcontrib>Blanc, Jean-Frédéric</creatorcontrib><title>Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - diagnostic imaging</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>Liver Neoplasms - diagnostic imaging</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Niacinamide - adverse effects</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Phenylurea Compounds - adverse effects</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Radiography</subject><subject>Treatment Outcome</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN1q1UAUhQdR7Gn1DUT2C-Q4P51J4oVSDtUWCoJW6F2Yn52eKZNMmJlQ-jI-qwlpvfRq3ay1114fIR8Y3QtG20-UN-esUXd7TpnY163kjXpFdkxJVnGu7l6T3WqpVs8JOc35gVLKRS3fkpNFmGhkvSN_rnDSJVoMYQ46gdXJ-jEOGkpCXdCBeYIck-5x9AYefTmCjcMUsCAk7XwM8d5bHSBhnuKYEbS1MTk_3kOJMPy8PFz_ugWbfMHk9Wc4xDk4eETIJU5Qjrg1DTiWr3Bh4lygj_P6Scb8jrzpdcj4_lnPyO9vl7eHq-rmx_frw8VNZQVvS2WolgKVskLWjJqGs9ZYK-raOeMMM7atXS2QCymVQWaaXhjaM6W0pKxXTpyR8-2uTTHnhH03JT_o9NQx2q24uxfc3Yq723AvsY9bbJrNgO5f6IXvYviyGfzYxzToI-pQjgtk7B6WkeOy6f8NfwEeVJLw</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Poullenot, Florian</creator><creator>Bioulac-Sage, Paulette</creator><creator>Laumonier, Hervé</creator><creator>Saric, Jean</creator><creator>Carteret, Thibault</creator><creator>Blanc, Jean-Frédéric</creator><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20140301</creationdate><title>Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases</title><author>Poullenot, Florian ; Bioulac-Sage, Paulette ; Laumonier, Hervé ; Saric, Jean ; Carteret, Thibault ; Blanc, Jean-Frédéric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-b0a53e66c35710b8219bcc377ddbdb1bc97d73e23556be1b8f3b0f166a501f6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - diagnostic imaging</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>Liver Neoplasms - diagnostic imaging</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Niacinamide - adverse effects</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Phenylurea Compounds - adverse effects</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Radiography</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poullenot, Florian</creatorcontrib><creatorcontrib>Bioulac-Sage, Paulette</creatorcontrib><creatorcontrib>Laumonier, Hervé</creatorcontrib><creatorcontrib>Saric, Jean</creatorcontrib><creatorcontrib>Carteret, Thibault</creatorcontrib><creatorcontrib>Blanc, Jean-Frédéric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poullenot, Florian</au><au>Bioulac-Sage, Paulette</au><au>Laumonier, Hervé</au><au>Saric, Jean</au><au>Carteret, Thibault</au><au>Blanc, Jean-Frédéric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>53</volume><issue>3</issue><spage>420</spage><epage>423</epage><pages>420-423</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><cop>England</cop><pub>Informa Healthcare</pub><pmid>23713857</pmid><doi>10.3109/0284186X.2013.795286</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 2014-03, Vol.53 (3), p.420-423 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_0284186X_2013_795286 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Taylor & Francis Journals Complete; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - surgery Dose-Response Relationship, Drug Humans Liver Neoplasms - diagnostic imaging Liver Neoplasms - drug therapy Liver Neoplasms - surgery Male Middle Aged Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - adverse effects Phenylurea Compounds - therapeutic use Radiography Treatment Outcome |
| title | Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A33%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatocellular%20carcinoma%20treated%20by%20sorafenib%20with%20complete%20radiological%20response%20according%20to%20mRECIST%20criteria:%20Could%20we%20stop%20the%20treatment?%20About%20four%20cases&rft.jtitle=Acta%20oncologica&rft.au=Poullenot,%20Florian&rft.date=2014-03-01&rft.volume=53&rft.issue=3&rft.spage=420&rft.epage=423&rft.pages=420-423&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.3109/0284186X.2013.795286&rft_dat=%3Cinformahealthcare_cross%3E10_3109_0284186X_2013_795286%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23713857&rfr_iscdi=true |